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Abstract
Glioblastoma multiforme (GBM) is the most common type of high-grade glioma and
accounts for as much as 50% of all primary brain tumors. With the current standard of
care, survival of GBM patients remains poor at 15 months after diagnosis. In this study,
the antiproliferative effects of a novel oxazine-4 derivative called 0108 were examined.
Delivery of 0108 was accomplished via complexation with (2-hydroxypropyl)-βcyclodextrin (HP-β-CD) to form 0108CD. The association constant, Ka, of 0108CD was
determined and stability of 0108CD formulations made with 1, 2.5, 5, 7.5, and 10% HPβ-CD were assessed over 24, 48, and 72 hours. The in vitro toxicity of 0108 and
0108CD was quantified via IC50 in U87-MG, U118-MG, SF298, and SF268 cell lines.
The effects of 0108 on cell phase were examined in U87-MG.
The 5% HP-β-CD formulation was established as the optimal 0108CD treatment based
on maximum 0108 encapsulation without HP-β-CD oversaturation. Stability of the 5%
HP-β-CD formulation decreased after 24 hours. Incorporating 0108 in a HP-β-CD
vesicle did not change the potency of the drug in SF295-MG and U118-MG, and
increased its potency in U87-MG and SF268-MG. 0108 treatment at the highest dose
showed a time-independent increase in the number of cells in G0/G1 and S phases and
a decrease in G2/M phase.
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Introduction
Cancers of the central nervous system (CNS) are leading causes of cancer deaths in
adults younger than 40 years with an estimated annual mortality of 128,000 out of the
176,000 diagnoses worldwide.1 Glioblastoma multiforme (GBM), a type of high-grade
glioma (HGG) or malignancy arising from the supportive tissue of the brain, is one of the
most frequently occurring and aggressive intracranial tumors. As of 2017, patients with
GBM had one-, five-, and ten-year survival rates of 39.7, 5.5, and 2.9%, respectively.1
The current standard of care in patients with GBM is maximal safe resection of the
tumor, followed by radiotherapy and adjuvant temozolomide (TMZ) chemotherapy. The
median survival for GBM patients receiving maximal therapy remains poor at 15 months
after diagnosis.1 Systemic delivery of TMZ is said to only result in moderate benefits,
attributed to its short serum half-life and numerous dose-limiting side effects, such as
blood toxicity and cardiomyopathy, suppression of bone marrow activity, and oral
ulcerations.2,3 Treatment of GBM and other CNS cancers is limited by the inability of
chemotherapeutics to cross the blood-brain barrier (BBB) and further, the blood-brain
tumor barrier (BBTB). In GBM specifically, the significant metabolic demands of the
HGG induce a hypoxic environment with overexpression of vascular endothelial growth
factor and angiogenesis, factors that disrupt the BBTB.4 The GBM core resembles this
disrupted BBTB which is highly “leaky” in nature. However, the invasive nature of
gliomas leaves the larger majority of the tumor with an otherwise intact BBTB with
similar characteristics to the BBB, including tight junctions, electrical resistance, and a
network of compound-inactivating enzymes.
Drug delivery systems offer an alternative to systemic delivery of chemotherapeutics.
They possess appropriate sizes, surface properties, and ligands which allow them to
penetrate the BBB and BBTB to offer targeted delivery of both hydrophilic and lipophilic
drugs. In recent years, researchers have been using drug delivery systems to enhance
TMZ treatment and reduce toxicity. One study, however, found that longer survival time
and reduction in tumor volume exhibited by the TMZ liposomal formulation were
statistically insignificant in comparison to free TMZ.5 The poor aqueous and organic
solubility of TMZ has led to significant difficulties in its encapsulation in polymeric
nanoparticles.6 Other modalities of TMZ delivery for treatment of GBM are being
studied, most notably, penetration of the BBB for direct delivery to the site of the lesion,
gold nanocarrier delivery systems, and nose-to-brain administration.
This work focuses on cyclodextrins (CDs), cyclic oligosaccharides that form noncovalent complexes with a range of hydrophobic drugs and increase drug bioavailability,
stability, and solubility. CDs promote drug absorption across the brain, dermal, nasal,
and intestinal barriers, a function attributed to their ability to extract cholesterol from

capillary endothelial cells and thereby inhibit activity of ATP-dependent efflux pump Pglycoprotein (P-gp).7 P-gp coats the surfaces of the aforementioned barriers and
removes foreign substances, like chemotherapeutics, from cells. There are three natural
CDs, α-, β- and γ-types with 6, 7, and 8 D-(+) glucopyranose units, respectively,
attached by α-(1, 4) glucosidic bonds.8 Of these, β-CD has been widely used in early
stages of pharmaceutical applications as its cavity size is ideal for the largest range of
drugs.
CD complexation with substrate drug molecules occurs in its internal hydrophobic cavity
via exclusion of high energy water from the internal cavity, release of ring strain of the
cyclic molecule, Van der Waals interactions, and hydrogen and hydrophobic binding.
Complexation can be studied via a phase solubility method in which phase solubility
diagrams are characterized into A, curves indicating soluble inclusion complexes, and
B, inclusion complexes with poorer solubility, types. β-CD often gives rise to B-type
curves due to their poor water solubility, whereas their chemically modified CDs like (2hydroxypropyl)-β-CD (HP-β-CD) produce soluble complexes and give A-type systems.9
Equilibrium binding of the drug and CD to form a 1:1 complex can be represented as:
𝐷𝑟𝑢𝑔 + 𝐶𝐷 ⇌ 𝐷𝑟𝑢𝑔 − 𝐶𝐷
Equation 1
In the case of a 1:1 complex, the association constant can be determined from the slope
of the linear portion of the curve using the formula:
𝐾* = 1
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Equation 2

2 (45,-./0)

where S0 is the intrinsic solubility of the drug studied under the conditions. Dilution, a
higher affinity guest, or transfer of the drug to a higher affinity matrix can cause easy
dissociation of the drug-CD complex.
A novel drug called 0108 (MW 409.86 g/mol), an oxazine-4 derivative, was studied for
its antiproliferative effects in this work. 0108 was allowed to complex with HP-β-CD to
form 0108CD (Figure 1).
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Figure 1: 1:1 complexation of HP-β-CD with 0108.
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The association constant, Ka, of 0108CD was determined and stability of 0108CD
formulations made with 1, 2.5, 5, 7.5, and 10% HP-β-CD were assessed over 72 hours.
IC50 values of 0108 and 0108CD in U87-MG, U118-MG, SF298, and SF268 cell lines
were determined. The effects of 0108 treatment on cell phase were examined in U87MG.
Materials
0108 dye was obtained from the Summer Gibbs lab at Oregon Health and Science
University. (2-hydroxypropyl)-B-cyclodextrin was purchased from Sigma-Aldrich (St.
Louis, MI). Cell culture supplies including Dulbecco’s Modification of Eagle’s Medium
(DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum
(FBS), trypsin ethylene-diamine-tetra acetic acid (EDTA), penicillin/streptomycin
(Pen/Strep) and Dulbecco's phosphate buffered saline (DPBS) were acquired from
VWR (Radnor, PA). U87-MG, U118-MG, SF-295, and SF-268 cell lines were purchased
from American Type Culture Collection (Manassas, VA). Vybrant® Dye Cycle™ Green
stain was purchased from Life Technologies (Grand Island, NY).
Methods
Complexation and stability of 0108CD formulations
A series of 1, 2.5, 5, 7.5, and 10% HP-β-CD solutions were prepared for complexation
with a suspension of 1.5 mg/mL of 0108. The complexes were dissolved in 95% EtOH,
followed by removal of the solvent at 50 °C for 12 minutes using the rotary evaporator.
Cyclodextrin thin films were hydrated at 50 °C and resulting formulations filtered using a
0.2 µm Nylon membrane syringe filter (VWR, Radnor, PA). Stability of freshly prepared
formulations were evaluated over 24, 48, and 72 hours by monitoring drug
complexation. Drug complexation was directly proportional to absorbance at 610 nm.
Measurements were done in triplicate, and data was presented as mean 0108
concentration (M) ± SD. The 5% HP-β-CD solution was established as the 0108CD
treatment in further studies.
In vitro toxicity of 0108 and 0108CD treatments
Cell viability was assessed for U87-MG, U118-MG, SF295, and SF268 at a density of
5,000 cells per well. U87-MG and U118-MG were cultured in DMEM media. SF295 and
SF268 were cultured in RPMI. All media were supplemented with 10% FBS and 1%
pencillin/streptomycin. The cells were grown in a 96-well plate at 37 °C, in a humidified
atmosphere, for 3 hours to allow for attachment. The cells were treated with 0.02, 0.2, 2,
20, 200, 2000, and 20000 nM of either 0108 or 0108CD. Control groups were treated
with either DMSO (0108 control) or water (0108CD control). After 72 hours, cell viability
was assessed using Resazurin solution at 10% of cell culture volume and fluorescence

intensity measured at excitation and emission of 560 and 590 nm, respectively, 2 hours
later.
Half-maximal inhibitory concentration (IC50) was determined with non-linear regression
analysis using GraphPad Prism version 6.05 for Windows, GraphPad Software (La Jolla
California, USA). Measurements were done in triplicate, and data presented as mean of
IC50 (nM) ± SD. A two-tailed unpaired t-test was performed at a p-value of 0.05 for
comparison between 0108 and 0108CD treatment groups.
Effect of 0108 on U87-MG cell phase
The effect of 0108 was studied on the cell cycle of U87-MG cells using Vybrant® Dye
Cycle™ Green stain. U87-MG cells were seeded at a density of 200,000 cells per well
in a 6-well culture plate and allowed 3 hours for attachment. Cells were then treated
with 30, 300, and 900 nM concentrations of 0108. The control groups were treated with
DMSO. Plates were incubated at 37 °C and effects on cell cycle studied at 24, 48, and
72 hours post treatment. After the incubation period, media was aspirated, and cells
were trypsinized and collected in 1.5 mL Eppendorf tubes. The cells were then
centrifuged at 3500 rpm for 3.5 minutes, the supernatant aspirated, and cells
reconstituted in new media. Centrifugation and reconstitution was repeated. Vybrant®
Dye Cycle™ Green stain was added, as per the manufacturer’s protocol, before
analysis with BD C6 Accuri software. The results for three replicates were presented as
mean percent of U87-MG cells ± SD in G0/G1, S, and G2/M phases.

Results and Discussion
The 1:1 complexation of HP-β-CD with 0108 was studied as a function of increasing
concentration of HP-β-CD (Figure 2) and the stability of each formulation was monitored
over 72 hours (Figure 3).

0108 Conc. (M)

0.004
0.003
0.002
0.001
0.000
0.02

0.04

0.06

0.08

HP-β-CD Conc. (M)

-0.001

Figure 1: 0108
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Figure 2: 0108 encapsulation as a function of HP-β-CD concentration. Data
presented as mean ± SD (n=3).
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0108 with 1, 2.5, 5, 7.5, and 10% HP-β-CD was encapsulated at concentrations of 0.91
± 0.039, 2.36 ± 0.057, 2.50 ± 0.121, 3.38 ± 0.250, and 3.31 ± 0.236 mM. Ka for
0108CD was determined by equation 2 to be 266.0 M-1. Stability of the 2.5 and 5% HPβ-CD formulations decreased after 24 hours. That of the 7.5% HP-β-CD formulation
decreased after 48 hours, and 1% and 10% HP-β-CD formulations became unstable
after 72 hours. The intrinsic solubility of 0108 in water was 0.121 mg/mL.
The 5% HP-β-CD formulation was established as the optimal 0108CD treatment for
further in vitro studies. This was based on maximum 0108 encapsulation without HP-βCD oversaturation.
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and 0108CD in GBM
lines. Data presented as

mean ± SD (n=3). *indicates statistical significance as compared to 0108
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treated cells (p-value <0.05).
In vitro cell viability for both free and encapsulated 0108 were evaluated in four GBM
cell lines to confirm that the CD complex did not modify the anti-proliferative effect of the
drug (Figure 4). The IC50 of 0108 in U87-MG, U118-MG, SF295-MG, and SF268-MG
was 312.5 ± 25.1, 436.8 ± 35.8, 661.3 ± 119.7, 768.2± 50.2 nM, respectively. The IC50
of 0108CD in U87-MG, U118-MG, SF298, and SF268 was 205.6 ± 15.4, 433.2 ± 131.8,
670.3 ± 27.5, and 589.5 ± 43.3 nM, respectively. The two treatments were statistically
indistinguishable at a p-value of 0.05 in SF295-MG and U118-MG. The IC50 of 0108CD
was lower than 0108 in U87-MG and SF268-MG. Incorporating 0108 in a cyclodextrin
vesicle did not change the potency of the drug in SF295-MG and U118-MG, and
increased its potency in U87-MG and SF268-MG.
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Figure 5: Effect of 0108 treatment below, around, and above IC50 in U87-MG cell cycle
over 72 hours. Data presented as mean ± SD (n=3). *indicates statistical significance
as compared to control at each time point (p-value <0.05).

Effect of the dose of 0108 on different phases of the cell cycle was studied in U87-MG
cells as a function of time (Figure 5). Cells were treated below, around, and above the
IC50 of 0108 and percent of cells in G0/G1, S, and G2/M phases evaluated at 24, 48,
and 72 hours. The percent of untreated cells in G0/G1 phase was 19.9, 19.4, and 23.3
at 24, 48, and 72 hours, respectively. The percent of cells in G0/G1 phase when treated
with 900 nM 0108 was 45.7, 49.9, and 48.6 at the aforementioned times, respectively.
The percent of untreated cells in S phase was 6.4, 6.7, and 7.9 while those with 900 nM
0108 treatment were 17.5, 13.4, and 12.7, respectively. The percent of untreated cells
in G2/M phase were 73.7, 73.9, and 68.8 and those treated with 900 nM 0108 were
36.8, 36.8, and 38.7, respectively. 0108 treatment at the highest dose showed a timeindependent increase in the number of cells in G0/G1 and S phases and decrease in
G2/M phase.
Conclusion
0108 and 0108CD were shown to have antiproliferative effects against GBM in vitro.
The efficacy of the CD formulation was similar to the free drug and even more potent in
U87-MG and SF268-MG cell lines. Stability of the 0108CD formulation decreased by 24
hours, but freeze-drying storage techniques may improve stability over longer periods of
time. Maximal treatment of 0108 shifted GBM cells from G2/M phase to G0/G1 and S
phases, highlighting the potential mechanism of the drug. Real-time cellular proliferation
and apoptosis studies of 0108 and 0108CD, and a comparison with well-known
chemotherapeutics including doxorubicin, may further establish the mechanism and
efficacy of this novel drug as a treatment for GBM.
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